TMCnet News
Achiko AG Strengthens Senior Team with Appointment of Head of Corporate Development
ZURICH, Switzerland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF) (SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce the appointment of strategic and corporate development executive David Hodge to the position of Head of Corporate Development and announces the retirement of Christophe Laurent as Board Director. Mr. Hodge brings over 30 years’ experience as a C-suite executive including Australia’s then largest private equity firm (SBC Capital Partners), global investment banking (UBS), global manufacturing (Amcor) and industrial services businesses (Worley), and technology software businesses, with a focus on shareholder value creation. His broad sector experience includes healthcare, manufacturing, technology, and banking and finance. He has been a strategic and corporate development advisor to world leading companies on business transformation and strategic challenges in emerging and developed markets, with a focus on profitable strategic growth. Clients have included ADM, Allnex, Amcor, AMVIG, Bayer, BTG, Campbells, Cornelius, Countrywide, Graphic Packaging International, MedHealth, NCO, Neovia, Nexans, Nine, SATS, SGH, Smith Group, Sumitomo, TGI Fridays, West Pharmaceutical, and Worley. Previously, Mr. Hodge led major capital raisings in Australia, Hong Kong, China, Southeast Asia, USA, and Europe. He has led global strategic projects on every major continent and implemented numerous M&A projects worldwide. Mr. Hodge has served as a Director and Chairman of public listed and private companies in Asia Pacific. He holds a Bachelor of Economics and Bachelor of Laws from Monash University in Australia. Mr. Hodge is responsible for the development of Achiko’s corporate presence especially in Switzerland, including forall matters regarding the development of the Board, corporate finance, and investor relations in its transformation to a world class diagnostics company. Mr. Hodge started his role as Head of Corporate Development on January 21, 2022. As previously announced, Board Director Christophe Laurent will retire on January 31, 2022. The Company will appoint a replacement for Mr. Laurent on or before the Annual General Meeting. “As the Company pursues CE Mark registration for our affordable, non-invasive Covid-19 rapid test AptameX™ in Q1 2022, we are excited to welcome Mr. Hodge to our senior team. His rich strategic and corporate development experience will bring a new dimension to Achiko as we prepare for commercialization beyond Indonesia,” said Achiko CEO Steven Goh. “In addition, the Board of Directors is grateful for the efforts of Mr. Laurent, and I would like to thank him personally as his broad contributions across the company helped grow Achiko to where we are today.” ABOUT ACHIKO AG Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX™ and companion health apps via its digital mobile health technology division, Teman Sehat™. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul, and Singapore. Media contacts: ACHIKO AG Switzerland & Global U.S. & Global Disclaimer 
|
